Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
NCT00630565 · Masonic Cancer Center, University of Minnesota · PHASE2/PHASE3 · terminated · last registry update 2024-01-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow Accrual” | – | Registry record, Masonic Cancer Center, University of Minnesota |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF2RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-22Results posted on the registry: Kiniksa Pharmaceuticals International, plc, mavrilimumab (NCT04447469)
- 2025-01-14Results posted on the registry: Ultimovacs ASA, UV1 + Sargramostim (NCT04382664)
- 2025-01-14Results posted on the registry: University of Florida, pp65-shLAMP DC with GM-CSF + unpulsed PBMC and saline (NCT02465268)
- 2024-12-09Results posted on the registry: Kristin Hudock, Mavrilimumab + Placebo (NCT04492514)
- 2024-11-19Results posted on the registry: Sellas Life Sciences Group, galinpepimut-S + pembrolizumab (NCT03761914)
- 2024-11-19Results posted on the registry: Sellas Life Sciences Group, Galinpepimut-S + GM-CSF (NCT01266083)
- 2024-10-09Results posted on the registry: Sellas Life Sciences Group, Galinpepimut-S + Montanide + GM-CSF + Montanide + GM-CSF (NCT01265433)
- 2024-10-08Results posted on the registry: Dendreon, sipuleucel-T (NCT03686683)
- 2024-09-19Results posted on the registry: National Cancer Institute (NCI), Cediranib + Sunitinib (NCT01391962)
- 2024-09-19Results posted on the registry: University of Washington, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine + Sargramostim (NCT02780401)
- 2024-09-19Results posted on the registry: Sellas Life Sciences Group, Galinpepimut-S + GM-CSF (NCT01827137)
- 2024-08-28Results posted on the registry: David Peereboom, Pembrolizumab + SurVaxM (NCT04013672)
- 2024-08-21Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Paclitaxel (NCT03498716)
- 2024-08-21Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Paclitaxel (NCT03498716)
- 2024-08-14Results posted on the registry: Children's Oncology Group, Dinutuximab + Irinotecan (NCT04385277)
- 2024-07-19Results posted on the registry: Nobelpharma, Sargramostim + Placebo (NCT04642950)
- 2024-07-03Results posted on the registry: Savara Inc., Molgramostim (NCT03482752)
- 2024-07-03Also stopped (terminated): Savara Inc., Molgramostim (NCT03482752)
- 2024-07-03Results posted on the registry: Savara Inc., Inhaled molgramostim + Antimycobacterial regimen (NCT03421743)
- 2024-06-17Also stopped (terminated): Aston Sci. Inc., AST-301(pNGVL3-hICD) + rhuGM-CSF (NCT05163223)
- 2024-05-29Phase 3 first posted: Savara Inc., Molgramostim (NCT06431776)
- 2024-04-08Results posted on the registry: Mustafa Khasraw, MBChB, MD, FRCP, FRACP, Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF + Temozolomide (NCT03927222)
- 2024-04-08Also stopped (terminated): Mustafa Khasraw, MBChB, MD, FRCP, FRACP, Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF + Temozolomide (NCT03927222)
- 2024-03-18Results posted on the registry: Y-mAbs Therapeutics, Naxitamab and GM-CSF in combination with irinotecan and temozolomide (NCT04560166)
- 2024-03-18Also stopped (terminated): Y-mAbs Therapeutics, Naxitamab and GM-CSF in combination with irinotecan and temozolomide (NCT04560166)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision